NCT03489850View on ClinicalTrials.gov

Ibudilast and Withdrawal-Related Dysphoria

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Alcohol Use Disorder
Interventions
DRUG

Ibudilast

Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.

OTHER

Placebo

Placebo is matched to ibudilast active medication.

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT03489850 - Ibudilast and Withdrawal-Related Dysphoria | Biotech Hunter | Biotech Hunter